Janux Therapeutics, Inc. (JANX) Misses Q3 EPS by 18c
Tweet
Share
E-mailGet Alerts JANX Hot Sheet
Join SI Premium – FREE
Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.51), $0.18 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $440 thousand versus the consensus estimate of $755 thousand.
For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Boeing lands two U.S. defense contracts worth over $711M
- Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
